Takeda Pharmaceutical CO LTD 13F institutional holdings
Quarterly disclosures of US equity positions held by institutional managers with over $100 million under management.
NYSE
Takeda Pharmaceutical Co Ltd disclosed its Q3 2025 equity portfolio, totaling $16.37 million across nine distinct positions, as detailed in its latest 13F-HR filing.
NYSE
Takeda Pharmaceutical Co Ltd filed its quarterly 13F-HR report, revealing $19.55 million in equity holdings across 12 companies as of June 30, 2025.
NYSE
Takeda Pharmaceutical Co. Ltd. reports its Q1 2025 holdings, revealing investments in various biotech and pharmaceutical companies.
NYSE
Takeda Pharmaceutical Co. Ltd. reports its holdings as of September 30, 2024, in a Form 13F filing with the SEC, revealing investments in various biotech and pharmaceutical companies.
NYSE
Takeda Pharmaceutical Co. Ltd. reports its Q2 2024 holdings, revealing significant investments in various biotech and pharmaceutical companies.
NYSE
Takeda Pharmaceutical Co. Ltd. reveals its equity holdings as of March 31, 2024, showcasing a diverse portfolio of investments in various biotechnology and pharmaceutical companies.
NYSE
Takeda Pharmaceutical Co. Ltd. reveals its equity holdings as of December 31, 2023, in its Form 13F filing.
NYSE
Takeda Pharmaceutical Co. Ltd. reports its Q4 2024 holdings, revealing investments in various biotech and pharmaceutical companies.